No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 83,415 | 59,382 | 23,798 | 53,741 | 45,009 | 31,696 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 49,437 | 39,334 | 2,039 | 16,602 | 8,319 | 8,318 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Aju IB Investment Co., Ltd., a venture capital and private equity subsidiary of AJU Corporation Co., Ltd., was established in 1974, initially operating as Kibo Technology Advancing Capital Co. Headquartered in Seoul, South Korea, with an additional office in Boston, Massachusetts, the firm is active in mezzanine financing, buyouts, corporate restructuring, and all stages of venture investments. Its primary focus is on small to medium-sized startup enterprises, predominantly in South Korea, though it also pursues international opportunities. For venture capital, it targets high-technology sectors, while private equity investments typically center on manufacturing. The firm's investment scope is broad, spanning information technology, including mobile service platforms, software, semiconductors, and digital content, as well as biotechnology, life sciences, and environmental solutions. It also delves into advanced information communication technologies such as the Internet of Things, artificial intelligence, smart car developments, and advanced materials. Specific medical areas of interest include companies developing immune system platform technology, oncology drugs, and ophthalmic pharmaceuticals. In South Korea, Aju IB Investment prioritizes companies that have achieved a rating of T5 or higher from technology credit bureaus. The Boston office maintains a specialized mandate, concentrating on therapeutics addressing significant unmet medical needs, enabling platform technologies with maturing lead candidates, potential partnerships with Korean pharmaceutical companies, and investments in medical devices and diagnostics. Financially, the firm generally invests between $0.87 million and $2.61 million for venture capital opportunities and between $4.36 million and $17.45 million for private equity transactions. Exit strategies commonly involve initial public offerings (IPOs) or mergers and acquisitions.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Aju IB Investment Co., Ltd. (027360.KQ)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Aju IB Investment Co., Ltd., a venture capital and private equity subsidiary of AJU Corporation Co., Ltd., was established in 1974, initially operating as Kibo Technology Advancing Capital Co. Headquartered in Seoul, South Korea, with an additional office in Boston, Massachusetts, the firm is active in mezzanine financing, buyouts, corporate restructuring, and all stages of venture investments. Its primary focus is on small to medium-sized startup enterprises, predominantly in South Korea, though it also pursues international opportunities. For venture capital, it targets high-technology sectors, while private equity investments typically center on manufacturing. The firm's investment scope is broad, spanning information technology, including mobile service platforms, software, semiconductors, and digital content, as well as biotechnology, life sciences, and environmental solutions. It also delves into advanced information communication technologies such as the Internet of Things, artificial intelligence, smart car developments, and advanced materials. Specific medical areas of interest include companies developing immune system platform technology, oncology drugs, and ophthalmic pharmaceuticals. In South Korea, Aju IB Investment prioritizes companies that have achieved a rating of T5 or higher from technology credit bureaus. The Boston office maintains a specialized mandate, concentrating on therapeutics addressing significant unmet medical needs, enabling platform technologies with maturing lead candidates, potential partnerships with Korean pharmaceutical companies, and investments in medical devices and diagnostics. Financially, the firm generally invests between $0.87 million and $2.61 million for venture capital opportunities and between $4.36 million and $17.45 million for private equity transactions. Exit strategies commonly involve initial public offerings (IPOs) or mergers and acquisitions.
